Clinical trial / 2008
A fungal beta-glucan preparation was tolerated by advanced cancer patients receiving chemotherapy.
In this phase I/II trial, 20 patients with advanced malignancies receiving chemotherapy received a beta-(1,3)/(1,6) D-glucan formulation. Investigators monitored participants for tolerability and effects on blood cell production. The authors concluded that the fungal supplement was well-tolerated and may have a beneficial effect on hematopoiesis during chemotherapy.
- Study type
- Phase I/II clinical trial
- Who was studied
- 20 patients with advanced malignancies receiving chemotherapy
- What was measured
- Tolerability and effects on hematopoiesis
THE PAPER
A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy.
Weitberg AB. J Exp Clin Cancer Res, 2008.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.